1-3 of 3
Joseph J. Drabick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Final Results of a Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (VCR) in Treating Mantle Cell Lymphoma

Jeffrey J. Pu, Kristin Berger, Chunlei Zheng, Nhan V Do, David F. Claxton, W Christopher Ehmann, Joseph J. Drabick, Thomas P. Loughran, Jr., Elliot Epner
Journal: Blood
Blood (2023) 142 (Supplement 1): 6152.
https://doi.org/10.1182/blood-2023-185797
Published: 2023
Journal Articles

The Mantle Cell Lymphoma Response to VCR Protocol Associated with Its Sensitivity to Hypomethylation Regulation-a Collateral Study on VCR Phase I Trial

Jeffrey J Pu, MD PhD, Matthew Nemesure, W. Christopher Ehmann, MD, David F Claxton, MD, Joseph J Drabick, MD, Anna C Salzberg, Yuka I Kawasawa, PhD, Elliot Epner, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5295.
https://doi.org/10.1182/blood-2018-99-118192
Published: 2018
Journal Articles

KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis

John C. Byrd, David M. Lucas, Andrew P. Mone, Joshua B. Kitner, Joseph J. Drabick, Michael R. Grever
Journal: Blood
Blood (2003) 101 (11): 4547–4550.
https://doi.org/10.1182/blood-2002-08-2623
Published: 2003